Reword and rewrite the following article in HTML, use a hip journalistic writing style and make the heading statements in H3 or bold font where necessary: By December 2025, medical cannabis prescriptions in Germany had increased by more than 3,300% compared with March 2024, the final month before cannabis was removed from the country’s narcotics law and reclassified as a non-narcotic medication. The shift simplified prescribing, opened the door wider for telemedical care and helped normalize cannabis as a regulated treatment.
That same shift also triggered a familiar reaction. Public claims of “misuse” started circulating. Draft policy ideas began pointing toward restrictions on telemedicine and distribution. A new Cannabis Barometer: 2025 Annual Review from Bloomwell Group argues those fears do not match the evidence and that tightening access could push patients back toward riskier, unlicensed options.
The analysis is based on an anonymized review of prescriptions redeemed by self-paying patients via a digital platform at partner pharmacies across Germany between January 2024 and December 2025. The report notes that the December 2025 data are extrapolated and could differ slightly later.
Prescriptions surged, and it was not a one-month spike
The report states that prescription volume reached an all-time high in December 2025. Compared with March 2024, prescriptions increased by more than 3,300%.
It also stresses that demand looked sustained, not fleeting. Even in the first quarter of 2025, monthly prescription volumes were already nearly 1,000% higher than March 2024, according to the analysis.
The report’s explanation is straightforward. The growth reflects streamlined access to legitimate care following reclassification, plus telemedical pathways that made it easier for patients to obtain a legal prescription and fill it through pharmacy channels.
Prices fell while product choice expanded
If the story stopped at prescription growth, it would still be notable. The price and supply data make it harder to dismiss.
The report shows the average price per gram of medical cannabis flower fell from €8.33 in January 2025 to €5.23 in December 2025, a decline of more than €3 across the year.
During the same period, product availability increased. The number of available cannabis flower products rose from 468 to 724, according to the report.
It also describes a market shift toward lower-cost options. By the end of 2025, flower priced below €6 per gram accounted for almost 80% of the supplied flower. The report adds that digital access has become efficient enough that total monthly treatment costs for many patients generally fall in the €30 to €50 range.
The “misuse” narrative does not hold up under clinical definitions
The report pushes back directly on the idea that more prescriptions automatically means abuse. It evaluates misuse claims against internationally recognized medical standards, including ICD-10 and DSM-5 criteria, which focus on measurable harm, impaired health outcomes, diminished quality of life and substance dependence.
Usin
